Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 16/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25975311 | 0.88 | PDE5A (0.39) | PDE5A | |
| SCHEMBL31120374 | 0.88 | PDE5A (0.39) | PDE5A | |
| SCHEMBL327167 | 0.84 | PDE5A (0.36) | PDE5AGRIN1GRIN2B | |
| SCHEMBL19264147 | 0.83 | SPR (0.38) | PDE5AGRIN1GRIN2B | |
| SCHEMBL14488284 | 0.82 | PDE5A (0.39) | PDE5A | |
| SCHEMBL14488354 | 0.81 | GRIN1 (0.37) | PDE5AGRIN1GRIN2B | |
| SCHEMBL15937696 | 0.80 | PDE5A (0.32) | PDE5AGRIN2B | |
| SCHEMBL14488171 | 0.79 | GRIN1 (0.37) | PDE5AGRIN1GRIN2B | |
| SCHEMBL326908 | 0.78 | PDE5A (0.44) | PDE5A | |
| SCHEMBL174461 | 0.78 | PDE5A (0.52) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729476-B1 | HETEROARYL SUBSTITUTED PYRAZOLOPYRIDINES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| EP-2729476-B1 | HETEROARYL SUBSTITUTED PYRAZOLOPYRIDINES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| US-20140228366-A1 | HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228366-A1 | HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228366-A1 | HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228366-A1 | HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B2, GUCY1B1 | PDE5A 8/4885GRIN1 3030/4885GRIN2B 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.